Gilead Sciences (NASDAQ: GILD) has announced a two-year extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX) focused on the discovery, development, and commercialization of targeted protein degradation therapies. As part of the agreement, Nurix will receive a USD 15 million extension fee for identifying novel agents that induce degradation of specified drug targets, while Gilead secures an option to license any resulting drug candidates.
This extension follows the successful partnership that produced GS-6791, a bivalent protein degrader targeting IRAK4, which Gilead in-licensed last year.- Flcube.com
